Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell CarcinomaNur P. Damayanti, Роберто Пили, Justin A. Budka et al.|Clinical Cancer Research|2018Cited by 95
EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome ReprogrammingRemi Adelaiye‐Ogala, Роберто Пили, Justin A. Budka et al.|Cancer Research|2017Cited by 74
Immunomodulation by HDAC inhibition: Results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, renal, and prostate carcinoma patients.Роберто Пили, Noah M. Hahn, David I. Quinn et al.|Journal of Clinical Oncology|2019Cited by 21
Integrative Multi-OMICs Identifies Therapeutic Response Biomarkers and Confirms Fidelity of Clinically Annotated, Serially Passaged Patient-Derived Xenografts Established from Primary and Metastatic Pediatric and AYA Solid TumorsPankita H. Pandya, Karen E. Pollok, Asha Jacob Jannu et al.|Cancers|2022Cited by 14
TFE3-Splicing Factor Fusions Represent Functional Drivers and Druggable Targets in Translocation Renal Cell CarcinomaNur P. Damayanti, Roberto Pili|Cancer Research|2024Cited by 9